Fate Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Fate Therapeutics

05/05/2022 09:49

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 68 cents​​ per share for the quarter ended in March. The
mean expectation of nineteen analysts for the quarter was for a
loss of 77 cents per share.
    * Revenue rose 65.3% to $18.41 million from a year ago; 
analysts
expected $9.40 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 68 cents​.
    * The mean earnings estimate of analysts had fallen by
about 13.6%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Fate Therapeutics Inc shares had fallen by 20.8% this
quarter and lost 47.5% so far this year.
    * The company reported a quarterly loss of $65.69 million.
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $90.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 17 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 5 at 08:49 a.m.  ​All
figures in US dollars unless otherwise stated